161262-45-9

Basic information

• Product Name: 3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one hydrochloride (1:1)
• Synonyms: 7H-Furo(3,2-g)(1)benzopyran-7-one, 3-((2-aminoethoxy)methyl)-2,5,9-trimethyl-, hydrochloride
• CAS NO: 161262-45-9
• Molecular Formula: C₁₇H₁₉NO₄*ClH
• Molecular Weight: 337.798
• Mol File: 161262-45-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 488.8°C at 760 mmHg
• Flash Point: 249.4°C
• Vapor Pressure: 1.06E-09mmHg at 25°C
• CAS DataBase Reference: 3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one hydrochloride (1:1)(161262-45-9)
• EPA Substance Registry System: 3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one hydrochloride (1:1)(161262-45-9)

Safety Data

• Hazardous Substances Data: 161262-45-9(Hazardous Substances Data)

Usage

General Description

3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one hydrochloride (1:1) is a complex chemical compound. 3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one hydrochloride (1:1) is characterized by the presence of a furochromenone core structure, which is common in various biologically active molecules. Its IUPAC name denotes its structure, such as a furochromenone structure (7H-furo[3,2-g]chromen-7-one), three methyl groups (trimethyl), and an aminoethoxy group attached via a methylene link. The hydrochloride indicates the presence of a hydrochloric acid molecule. While there is limited information regarding this specific compound, similarly structured molecules are often studied for their potential pharmacological activities.

Synthetic route

trioxsalen (3902-71-4) → 4'-(4-amino-2-oxa)butyl-4,5',8-trimethylpsoralen Hydrochloride (161262-45-9)

Upstream product

• 3902-71-4 trioxsalen 

Relevant articles and documents

Methods and devices for the removal of psoralens from blood products

Methods and devices for the removal of psoralens and psoralen photoproducts from blood products are described. The methods include contacting a psoralen- and irradiation-treated blood product with a resin capable of adsorbing psoralens and psoralen photoproducts. The removal process is particularly suitable for use with platelet concentrates and plasma because the process does not have a significant adverse effect on clotting factor function. The methods and devices can be incorporated with apheresis systems and other devices and procedures currently used to process blood products for transfusion.

Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.